atomoxetine + buspirone

A combination of atomoxetine and buspirone that has been studied in clinical trials for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults. Atomoxetine is a selective norepinephrine reuptake inhibitor, while buspirone is an anxiolytic medication. The combination was investigated to determine if adding buspirone to atomoxetine treatment would provide enhanced efficacy compared to atomoxetine monotherapy. An 8-week, randomized controlled trial published in 2012 showed that the decrease in the primary efficacy measure (AISRS total score) was significantly greater for the atomoxetine-buspirone combination than placebo, but the difference compared to atomoxetine monotherapy was only statistically significant at one time point (week 4). Common adverse events included insomnia, nausea, dry mouth, headache, and asthenia, with dizziness frequently reported specifically for the atomoxetine-buspirone group. Potential interactions include an increased risk of hypertension.